NVILE forecast ·
Abbott (ABT) Stock Forecast: Next 30 Days
Abbott Laboratories (ABT) is projected to trade within an 80% calibrated range of $101.70 to $120.84 over the next 30 days, based on an event-volatility distribution model from its $110.16 close. There is an estimated 5% probability of a decline exceeding 10% and a 10% probability of an increase exceeding 10%. With elevated volatility and no tested directional edge from price history alone, the midpoint of $110.86 represents a statistical center rather than a price target.
Price now
$110.16
Nov 2, 2026
In 30 days
$110.86
NVILE forecast
Expected move
+0.6%
Range
$101.70–$120.84
What to do
- Calibrate equity exposure around the $101.70 to $120.84 band rather than relying on directional targets.Elevated volatility and symmetric distribution curves show limited directional predictive edge over a 30-day horizon.
- Hedge downside tails using put spreads below $101.70 or scale back tactical longs near the $118 consensus average.[2],[3],[4]High short volume (56.8%) and heavy insider selling above $115 signal capping resistance against further upside.
Why
- Calibrated distribution modeling establishes an 80% 30-day trading range of $101.70 to $120.84, with a 54% probability of positive return.
- Finra short-sale volume reached 56.8% of daily volume on November 2, elevated above its 5-day (48.7%) and 20-day (43.4%) moving averages.[2]
- Wall Street consensus maintains an average 12-month target of $118.52 (range $100.00 to $130.00), despite zero upward EPS revisions in the past 30 days.[4]
- Integration of Exact Sciences, completed in March 2026, expanded diagnostic sales following initial term bridge financing of up to $20.0 billion.[1],[5]
- Technical breakout momentum registered a latest return z-score of +2.28 against historical 20-day return volatility.
What could go wrong
How it connects
- Abbott Laboratoriescompleted acquisition ofExact Sciences Corporation[5]
- Robert B. Fordserves as Chairman and CEO and sold 398,832 shares ofAbbott Laboratories[3]
- Louis H. Morroneserves as Executive VP and sold 5,850 shares ofAbbott Laboratories[3]
- Food and Drug Administrationgranted regulatory approval forTendyne TMVR System[1]
- Financial Industry Regulatory Authoritytracks Reg SHO daily short-sale volume forAbbott Laboratories[2]
- Abbott Laboratorieslists primary voting common stock onNew York Stock Exchange[1]
NVILE's track record on this page
| Made | Forecast | Actual | Result |
|---|---|---|---|
| Nov 3, 2026 | $110.86 | Due Dec 3, 2026 | Pending |
Every published call is scored when it comes due. See all results →
Sources
Questions
What is the Abbott forecast for the next 30 days?
NVILE's models put Abbott at about $110.86 in 30 days, +0.6% from $110.16. Abbott Laboratories (ABT) is projected to trade within an 80% calibrated range of $101.70 to $120.84 over the next 30 days, based on an event-volatility distribution model from its $110.16 close. There is an estimated 5% probability of a decline exceeding 10% and a 10% probability of an increase exceeding 10%. With elevated volatility and no tested directional edge from price history alone, the midpoint of $110.86 represents a statistical center rather than a price target.
What price range does NVILE expect for Abbott?
The forecast range is $101.70 to $120.84 over 30 days. Prices outside this range are possible; the range describes the model's scenarios, not a guarantee.
What could change the Abbott outlook?
Elevated short-sale share of volume indicates rising hedging or tactical short positioning following recent price appreciation. Substantial executive share disposals, including over 398,000 shares sold by CEO Robert Ford at $115–$116, signal limited insider accumulation near current levels.
What should investors watch or do about Abbott?
Calibrate equity exposure around the $101.70 to $120.84 band rather than relying on directional targets. Hedge downside tails using put spreads below $101.70 or scale back tactical longs near the $118 consensus average.
How accurate are NVILE forecasts?
Every forecast NVILE publishes is scored against the real price when it comes due, and the results are listed on NVILE's public accuracy ledger.
This page is generated by NVILE's research models from public sources and market data. It is not financial advice, and forecasts can be wrong.